# Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

> **NCT05301842** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 760 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tremelimumab
- **DRUG:** Durvalumab
- **PROCEDURE:** Transarterial Chemoembolization (TACE)
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05301842
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2026-02-23
- **Final completion:** 2027-02-26
- **Target enrollment:** 760 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05301842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05301842, "Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05301842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*